Zofran Lawsuit Plaintiff Alleges Infant Was Born With Hypoplastic Right Heart Syndrome Due To Fetal Drug Exposure

March 14, 2016 – – ZofranLegal.com reports on another birth defect lawsuit which has been filed against pharmaceutical giant GlaxoSmithKline in regard to the anti-nausea drug they manufacture, Zofran. This complaint was filed by a mother from Illinois, who alleges that due to fetal exposure to the drug through her body while pregnant, her son developed a serious heart defect. The woman indicates that manufacturer GSK’s, “conduct has caused devastating, irreversible, and life-long consequences and suffering to newborns and their families.” She makes this blanketed statement as she is just one of hundreds of parents who have stepped forward with very similar birth defect allegations against the defendant.

Details found within the court documents of this lawsuit indicate that the mother was prescribed Zofran while pregnant, as many are. She used the drug during her first trimester when plagued by nausea from morning sickness. Her case is similar to many plaintiffs who have filed Zofran birth defect lawsuits, as the first trimester is the most common time for expectant mothers to experience nausea and vomiting episodes. Unfortunately, the first trimester is also a time when a fetus does much of its initial heart, limb, and mouth tissue development. The plaintiff in this case reports that after taking Zofran, her pregnancy progressed normally, until she gave birth to her son in 2012. At this time, the infant boy was immediately diagnosed with hypoplastic right heart syndrome.

Hypoplastic right heart syndrome is a congenital birth defect which develops when the right side of the heart becomes malformed and cannot properly pump blood. It can greatly restrict blood flow to the lungs, and cause many infants with this condition to develop a bluish tinge on their lips, fingernails, or other body parts.

The plaintiff states that physicians informed her that her infant son required a heart transplant surgery. Given the size and strength of the baby, this was deemed a high-risk procedure. Today, after experiencing pain, suffering, and significant medical bills, the plaintiff is seeking damages to help cover costs. She states that she will likely have future medical bills as well, since her son continues to require medical care.

Zofran manufacturer GlaxoSmithKline has angered many mothers from across the U.S., who share a common point of extreme contention: Zofran was prescribed to them ‘off-label’, as it was never given FDA-approval to treat pregnant women or even tested for safety on these women and their unborn babies. Instead, the drug was specifically FDA-approved to treat patients battling nausea and vomiting after undergoing certain medical procedures, such as chemotherapy, radiation, or anesthesia. Despite this fact, manufacturer GSK went on to market the drug as a safe and effective treatment for morning sickness ‘off-label’. While very controversial, many patients given the drug were unaware, and this marketing tactic led to an estimated 1 million ‘off-label’ Zofran prescriptions to expectant mothers in just one year’s time.

As lawsuits against GSK and Zofran continue to increase in number steadily, the attorneys of Monheit Law are working to help ensure that women who have taken Zofran while pregnant and who have also given birth to children with defects will be provided the important opportunity to investigate their legal rights in full. The women, families, and children affected may be entitled to legal action and substantial compensation. To help those most deserving pursue justice, the attorneys of Monheit Law are currently offering complimentary legal consultations for those affected.

To request additional Zofran birth defect information, or to ask questions, please contact attorney Michael Monheit of Monheit Law by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008669